Skip to content
DraconiticResearch
Search Sources API
216,686 studies31 sourcesUpdated 50 min ago

Oncology

5,539 studies453 in 7 days2,591 in 30 days

Filters
Type
Date
Clear

Latest

5,539 studies

  1. An integrated Phase II/III randomized study comparing durvalumab and tremelimumab ± Hepatic ArteriaL infusion chemotherapy with GEMOX in hepatocellular Carcinoma with high tumor burdEn – ALICE (PRODIGE89 – UCGI44 – ALICE)
    Octave Letissier, Xavier Adhoute, Boris Campillo-Gimenez +21
    Digestive and Liver DiseasePeer-reviewedCC BY-NC-NDFull textOncologyHAL
  2. Diagnostic pitfalls and unmet needs in neuroendocrine neoplasms: The added value of collegial expert pathology review through the national TENpath network
    Matthieu Tihy, Jean-Yves Scoazec, Serge Guyétant +30
    European Journal of CancerPeer-reviewedCC BY 4.0Full textOncologyHAL
  3. Hypercapnia Induces Mitochondrial Adaptations and Alters Glutamine Metabolism to Drive a Distinct Metabolic Phenotype in Monocytes
    Ben Reddan, David E. Phelan, Xiaofei Yin +3
    Immunology and Cell BiologyPeer-reviewedCC BY 4.0Full textOncologyPMC
  4. Immunometabolic interactions in gynecologic cancers: Mechanisms, biomarkers, and therapeutic implications
    Agapiti H. Chuwa, David H. Mvunta
    The Journal of International Medical ResearchPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  5. Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma
    A. G. Shea, A. Ollendorff, A. Wilke +18
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  6. Biochemical and Mechanistic Characterization of the DNA-dependent Poly(ADP-ribose) Polymerase, MoPARP1, in Magnaporthe oryzae
    N. Payne, R. E. Kalicharan, A. Reyes-Kildare +1
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv
  7. Resource limitation rewires chromosome instability and ploidy evolution across in vitro and in vivo cancer models
    T. Li, R. Beck, V. Tagal +2
    bioRxivPreprintCC BY-NCFull textOncologybioRxiv
  8. In vivo intercellular CRISPR screens using viral proximity barcoding reveal regulators of tumor-immune interactions
    P. Du, S. Kohno, M. Wang +11
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  9. Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition
    M. P. East, J. F. Olivares-Quintero, D. O. Okumu +25
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  10. SRPK1 is a determinant of chemoresistance to Docetaxel in prostate cancer
    D. Duzgun, W. Read, S. Oltean
    bioRxivPreprintCC BYFull textOncologybioRxiv
  11. Oncogenic fusions induce an extensive cancer-restricted cryptic proteome in Ewing sarcoma
    L. A. Broeils, J. Pilet, M. K. Koshkina +38
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  12. A Tumor-Pituitary-Stromal Axis Promotes Colorectal Cancer Progression
    W. Li, S. Wang, H. Wu +9
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  13. RNA binding proteome profiling reveals RNA-dependent activation of oncogenic host signaling during KSHV infection.
    Yang Zhao, Xiang Ye, Madeline Yuen +3
    Nature communicationsPeer-reviewedCC BYFull textOncologyEurope PMC
  14. Targeting Polθ Helicase with RP-3467: Preclinical Validation and Clinical Response in a gBRCA1 ovarian cancer patient with an acquired PARPi resistance mutation in TP53BP1
    A. Sfeir, E. Rosen, M.-C. Mathieu +29
    medRxivPreprintCC BYFull textOncologymedRxiv
  15. Validating LLM judges for automated oversight of patient communication
    Z. Xu, J. Zeng, S. Zhou +16
    medRxivPreprintCC BY-NCFull textOncologymedRxiv
  16. Population-Scale Precision Safety in Oncology Reveals Clinical and Genetic Determinants of Systemic Therapy Toxicity
    Z. Bakouny, X. A. Guo, F. Huang +34
    medRxivPreprintCC BY-NC-NDFull textOncologymedRxiv
  17. Comparative evaluation of ChatGPT and gemini responses to patient-oriented questions on breast cancer
    Yeliz Yilmaz Bozok, Nihan Acar, Murat Kemal Atahan +1
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologyPLOS
  18. From in silico prediction to experimental validation: Identification of drugs and novel synergistic combinations that inhibit growth of inflammatory breast cancer cells
    Esraa A. Salim, Xiaojia Ji, Michael Tarpley +4
    PLOS OnePeer-reviewedCC BY 4.0Full textOncologyPLOS
  19. A Review of Computational Modeling of Cancer Metastasis
    Romain Zakrajsek, David Boulate, Sébastien Benzekry
    HALPreprintCC BY-NC-SA 4.0Full textOncologyHAL
  20. Lumican - derived peptides inhibit melanoma cell growth and migration.
    Katarzyna Pietraszek-Gremplewicz, Stéphane Brézillon, Corinne Perreau +3
    PLoS ONEPeer-reviewedCC BY 4.0Full text65 citedOncologyPharmacology & toxicologyHAL
  21. Molecular Evolution of the Thermosensitive PAb1620 Epitope of Human p53 by DNA Shuffling
    Dimitris Xirodimas, David Lane
    Journal of Biological ChemistryPeer-reviewedCC BY25 citedOncologyHAL
  22. Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo
    Mark Saville, Alison Sparks, Dimitris Xirodimas +5
    Journal of Biological ChemistryPeer-reviewedCC BY158 citedOncologyHAL
  23. p14 Arf Promotes Small Ubiquitin-like Modifier Conjugation of Werners Helicase
    Yvonne Woods, Dimitris Xirodimas, Alan Prescott +3
    Journal of Biological ChemistryPeer-reviewedCC BY59 citedOncologyHAL
  24. Perturbation of 60 S Ribosomal Biogenesis Results in Ribosomal Protein L5- and L11-dependent p53 Activation
    Xiao-Xin Sun, Yue-Gang Wang, Dimitris Xirodimas +1
    Journal of Biological ChemistryPeer-reviewedCC BYFull text80 citedOncologyHAL
  25. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation
    Nieves Embade, David Fernández-Ramos, Marta Varela-Rey +14
    HepatologyPeer-reviewedLicence not stated1 citedOncologyHAL